Strides Arcolab gets Canadian nod for Ondansetron injection

New Delhi, Aug 8 (UNI) Pharma company Strides Arcolab Ltd today said it has received first Abbreviated New Drug Submission (ANDS) approval for its Ondansetron Injection 2 mg/ml.

The product is licensed to an undisclosed partner in Canada and expects sales to commence from the fourth quarter of current fiscal, company said in a statement.

''We are delighted with our first Canadian approval for an important sterile product and are delighted having achieved a further milestone in creating a global sterile injectable business,'' company's Vice Chairman and Managing Director Arun Kumar said.

Ondansetron is a first amongst various sterile submissions the company has submitted with Health Canada.

UNI